Amgen announced today that its LDL-lowering anti-PCSK9 antibody Repatha (Evolocumab) drug met its primary endpoint for reducing MACE events. No data available yet, but full results at the ACC meeting next month. 

This doesn't directly affect Resverlogix, since LDL-lowering isn't the mechansim of action of RVX-208. However, it does indirectly affect Resverlogix since this may add another approved drug to the toolbox that has been shown to reduced MACE. Recall the diabetes drugs Jardiance and Victoza both showed reduce MACE recently. We don't know the magnitude of the Repatha MACE lowering yet. So today's news doesn't alter the great potential of RVX-208 to hit a home run as a first in class BET inhibitor to the market with remarkable MACE reduction.

BearDownAZ